Compare Medpace Holdings Inc (MEDP) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Medpace Holdings Inc trades at $613.05 (market cap $16.82B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Ultra Short Bond ETF for 61 Days on average.
| MEDP | VUSB | |
|---|---|---|
Market Cap | $16.82B | $10.20B |
Volume | 223,093 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $630.19 | $50.03 |
52-Week Low | $393.42 | $49.41 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
VUSB trades at $49.48, up 0.08% with minimal daily movement. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $50 and support at $49. Recent news highlights potential benefits from short-term bond strategies amid Federal Reserve rate uncertainty.
The outlook remains cautious due to bearish technical signals and interest rate sensitivity. Opportunities include dividend stability with recent payouts, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term bond appeal against broader economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
